TheraVet Signs an Important Distribution Agreement With the Orthopaedics & Surgical Instrumentation Distributor, Veterinary Instrumentation
10 Mai 2022 - 7:30AM
Business Wire
- Distribution agreement for the new BIOCERA-VET® product line
including Bone Surgery - Ready to Use, Osteosarcoma Ready to Use,
Granules & Smartgraft - in United Kingdom and Ireland
- Key marketing and sales support for the upcoming commercial
launch of these products in United Kingdom and Ireland
Regulatory News:
TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN:
BE0974387194 - ticker: ALVET), a pioneering company in the
management of osteoarticular diseases in pets, announces today
the signing of an exclusive distribution agreement with
Veterinary Instrumentation (Vi), a global animal-health company
specialising in orthopaedics & surgical instrumentation.
This agreement represents a significant step forward for the
distribution of BIOCERA-VET® product line in United Kingdom, the
third largest European market with more than 16 million of
companions (dogs and cats) in UK, and Ireland.
Enrico Bastianelli, Chief Executive Officer of TheraVet,
comments: “Veterinary Instrumentation, with its focus in vet
surgery and orthopaedics, is the partner of choice to quickly and
broadly reach BIOCERA-VET customers and users. With this major
agreement, TheraVet is now able to address this important
veterinary market.”
Under the terms of the agreement, Veterinary Instrumentation
will leverage its own sales and marketing strikeforce in the
veterinary field to promote and distribute the BIOCERA-VET®
products in United Kindgom and Ireland.
This distribution agreement includes the products recently added
to TheraVet bone substitutes portfolio i.e., BIOCERA-VET® Bone
Surgery Ready To Use, BIOCERA-VET® Osteosarcoma Ready To Use,
BIOCERA-VET® Granules and BIOCERA-VET® SmartGraft.
Commercialization of the products, perfectly positioned to meet the
needs of veterinarians in terms of ease of use, compliance with
current standards and results, in anticipated in the coming
weeks.
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for companion animals. The Company
develops targeted, safe and effective treatments to improve the
quality of life of pets suffering from joint and bone diseases. For
pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris and Brussels, has its head office
in Belgium (Gosselies) with a US subsidiary in Texas.
For more information, visit the TheraVet website
Or follow us on LinkedIn / Facebook / Twitter
About Veterinary Instrumentation
Veterinary Instrumentation is a global animal-health company
specialising in Orthopaedics & Surgical Instrumentation founded
in 1986. With a portfolio of over 5,000 products to select from, a
dynamic and comprehensive range of Surgical and Orthopaedic
Instrumentation, Joint Surgery and Fracture Fixation products,
allow practices and users to consolidate and drive value from their
clinical service through one reputable source. The quality and
efficacy of products is demonstrated through 19,000 Vi products
being implanted each year. Veterinary Instrumentation is
headquartered in Sheffield, United Kingdom and serves more than 65
countries around the globe.
For more information about Veterinary Instrumentation visit
veterinary-instrumentation.co.uk/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220509005867/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43 Chief Corporate
Officer Julie Winand investors@thera.vet NewCap Investor
Relations and Financial Communications Théo Martin / Olivier
Bricaud theravet@newcap.eu Tel: +33 (0)1 44 71 94 94 Press
Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu Tel: +33
(0)1 44 71 00 15 NewCap Belgique Press Relations Laure-Eve
Monfort lemonfort@newcap.fr Tél. : + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
TheraVet (EU:ALVET)
Historical Stock Chart
Von Apr 2023 bis Apr 2024